Laurus Labs climbs 6% on USFDA approval

INSUBCONTINENT EXCLUSIVE:
Shares of Laurus Labs climbed 6 per cent on Thursday after the pharma company received USFDA approval for a generic drug used in treatment
of diabetes
The stock rose 5.84 per cent to hit a high of Rs 464.35 on the BSE. In a filing to BSE, the drugmaker said the US regulator has okayed
Metformin Hydrochloride Tablets USP 500 mg, 850 mg and 1,000 mg
This is therapeutically equivalent to Glucophage Tablets 500 mg, 850 mg, and 1,000 mg of Bristol-Myers Squibb Company. The product and API